Report Overview

The EU Head and Neck Cancer Drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Cancers of the head and neck are categorized depending on the location. These areas include the oral cavity, pharynx, larynx, paranasal sinuses & nasal cavity, and salivary glands. An increase in consumption of alcohol and tobacco is a major cause of head and neck cancer. An estimated 75% of head and neck cancers are caused due to consumption of alcohol and tobacco. An increase in the number of head and neck cancer patients across the world is anticipated to drive demand for therapeutics. Head and neck cancers are the 6th most common type of cancer in the EU. According to the world health organization survey, it is found that every year 550,000 cases with nearly 300,000 deaths are recorded due to neck and head cancers. Despite its severity and increasing prevalence within society, there is little awareness of head and neck cancer, 60% of people diagnosed at an advanced stage die from the disease within 5 years. An increase in immunotherapy adoption is an opportunity for players to capitalize on and expand further in other regions. PD inhibitors are likely to capture a significant market share and help expand overall franchise revenue

Market Growth Drivers

Amongst all the types of cancers, head and neck cancers are one of the common kinds occurring in recent times. The increase in the number of the patient population with head and neck cancers and is a significant growth factor for the head and neck cancer market. Current trends indicate that the rising geriatric population worldwide, growing cases of target diseases, and the availability of improved healthcare services due to government and private organization initiatives will drive the overall market